Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

FED × Oligodendroglioma × CNS × Clear all

Phase

Status

Sponsor Class

OTHER 208 NIH 72 INDUSTRY 35 NETWORK 34 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Rare Diseases 2 Glioma 2 Glioblastoma 2 Genetic Diseases, Inborn 2 Oligodendroglioma 1 Neuroma, Acoustic 1 Neurologic Manifestations 1 Neurofibromatosis 2 1 Neurofibromatoses 1 Mental Disorders 1 Hearing Loss 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Streptozocin 1 Mercaptopurine 1 Carmustine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡